Resiquimod (R848) 以剂量依赖性方式增强 PBL 增殖，并增加 BrdU 掺入试验中 BrdU 阳性细胞的数量。 用 R848 处理的细胞表现出显著增加 (3.5 倍) 的荧光素酶 ( NF-κB 活性的报告分子) 活性 [3] 。

R848 (Resiquimod), an imidazoquinoline, is a dual TLR8 and TLR7 synthetic agonist with potent antiviral activity. InvivoGen R848 (≥95% HPLC) is water soluble, functionally tested on TLR7 and TLR8 cellular assays, and guaranteed endotoxin-free.

Resiquimod (R848) enhances PBL proliferation in a dose-dependent manner, and increases the number of BrdU-positive cells in BrdU incorporation assay. Cells treated with R848 exhibits significantly increased (3.5-fold) luciferase (a reporter of NF-κB activity) activity.

Resiquimod (R-848, S28463)是一种免疫反应调节剂，用作有效的 TLR 7/TLR 8 激动剂并可诱导如 TNF-α 、 IL-6 和 IFN-α 等细胞因子的上调。 Resiquimod 可减少 hepatitis C virus (HCV)感染。 Phase 2。 Induction of type 1 IFN secretion in human PBMC at 300 nM after 18 hrs by ELISA, Activity=0.00726μM. Induction of type 1 IFN secretion in human PBMC at 100 nM after 18 hrs by ELISA, Activity=0.00561μM.

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel [1] in the treatment of skin lesions [2] such as those caused by the herpes simplex virus [3][4] and cutaneous T cell lymphoma, [5] and as an adjuvant to increase the effectiveness of vaccines. [6] .

2019年10月15日 · R848-treated mice demonstrated improvements in behavioral and molecular cachexia manifestations, resulting in a near-doubling of survival duration. Knockout mouse studies revealed that stromal,...

R848 (Resiquimod) is an imidazoquinoline compound with potent anti-viral activity1-3. This low molecular weight synthetic molecule is a selective activating ligand for both TLR7 and TLR8 in humans but only TLR7 in mice.

雷西莫特 (R-848)是一种有效的TLR7/TLR8合成激动剂，具有抗病毒和抗肿瘤活性。 雷西莫特属于咪唑喹啉胺类化合物，具有免疫调节作用。 雷西莫特可提高细胞因子的水平，如TNF-α、IL-6和IFN-α。 [7] [8] 雷西莫特是toll样受体7和8（TLR-7和TLR-8）的激动剂。 《受体分类和信号转导》手册的 细胞因子受体（白细胞介素-1受体/TIR家族） 页面有该化合物的介绍。 想要浏览手册的其他页面， 请单击此处。 没有发现合适的版本？ 如果您需要特殊版本，可通过批号或批次号查 …

Resiquimod (R848) (GMP) is Resiquimod produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages